# Janus Henderson Investors

> Janus Henderson Investors is a VC fund backing Biotechnology and Health Care. See 231 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 231
- Last investment: Jul 2026
- Lead investor: 13%
- Last fund: Aug 2024
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/janus-henderson-us
- X (Twitter): https://twitter.com/jhiadvisorsus
- Website: https://www.janushenderson.com/henderson
- Facebook: https://www.facebook.com/pg/JanusHendersonUS

Janus Henderson Investors is a VC fund in London focused on Biotechnology and Health Care. Janus Henderson Investors focuses on investing performance and services. The firm connects institutional, retail, and high-net-worth clients with investment specialists who specialize in a variety of asset classes, such as equities, fixed income, real estate, and alternatives.

## Contacts

5 contacts available for Janus Henderson Investors. Shizune tracks 11 team members at Janus Henderson Investors. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/janus-henderson-investors?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 117 | 51% |
| Health Care | 69 | 30% |
| Therapeutics | 45 | 19% |
| Medical | 44 | 19% |
| Biopharma | 30 | 13% |

74 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 50 | 22% |
| Post-IPO Equity | 34 | 15% |
| Series C | 23 | 10% |
| Series A | 19 | 8% |
| Series D | 9 | 4% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 116 | 50% |
| Canada | 4 | 2% |
| United Kingdom | 4 | 2% |
| China | 3 | 1% |
| India | 1 | 0% |

11 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Vish Sridharan | Research Analyst | 3 | https://shizune.co/investors/profile/vish-sridharan |
| David Kowalski | Former Chief Risk Officer | 0 | https://shizune.co/investors/profile/david-kowalski-8df9 |
| David Master | Global Chief Marketing Officer | 0 | https://shizune.co/investors/profile/david-master-5e67 |
| Enrique Chang | Global Chief Investment Officer | 0 | https://shizune.co/investors/profile/enrique-chang-243f |
| John Lloyd | Co-Head of Credit Research and Portfolio Manager | 0 | https://shizune.co/investors/profile/john-lloyd-4 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LB Pharmaceuticals | LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual propertyaround improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia. | $150M | Post-IPO Equity | Jul 29, 2026 |  |
| Processa Pharmaceuticals | Processa Pharmaceuticals operates as a pharmaceutical company. The company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. | $200M | Post-IPO Equity | Jul 29, 2026 |  |
| Claris Biotherapeutics | Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M | Series B | Jul 28, 2026 |  |
| Mentari Therapeutics | Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M | Private Equity | Jul 22, 2026 |  |
| Draig Therapeutics | Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses. | $65M | Series B | Jul 14, 2026 |  |
| Lycia Therapeutics | Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M | Series D | Jun 25, 2026 |  |
| Triveni Bio | Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets. | $65M | Series C | Jun 17, 2026 |  |
| Ethena | Ethena provides a synthetic dollar protocol on the Ethereum blockchain that supports a crypto-native form of digital money. The protocol issues USDe, a synthetic dollar backed by crypto assets and short futures positions, using delta hedging to maintain stability relative to the US dollar. Ethena also introduces sUSDe, a yield-bearing version ofUSDe that allows holders to stake their assets and earn returns from protocol operations. In addition, the platform includes a governance token, ENA, which enables participation in decisions on risk management, integrations, and updates. Ethena integrates with both decentralized and centralized finance platforms, offering transparency and tools that support ecosystem composability. |  |  | Jun 02, 2026 |  |
| SmartMedia Technologies | SmartMedia Technologies is the Enterprise Web3 platform the future is being built on. The SmartMedia Stack, including its self-serve, no-code, drag and drop NFT and Web3 design studio, makes Web3 easy for users and Enterprise. It leverages the scale and reach of its Web3-enabled programmatic media platform. SmartMedia Technologies’ end-to-endWeb2-to-Web3 platform drives engagement, acquisition and loyalty across a digital and mobile-first audience - delivering better business outcomes. |  |  | Jun 02, 2026 |  |
| Oak hill bio | Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines. | $32.5M | Series A | Jun 01, 2026 |  |

10 of 231 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 78 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 61 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 41 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 39 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 38 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 38 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Janus Henderson Investors invest in?

Janus Henderson Investors invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Post-IPO Equity stage. Most of the 231 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Janus Henderson Investors?

Public channels for Janus Henderson Investors include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Janus Henderson Investors?

The team at Janus Henderson Investors includes Vish Sridharan (Research Analyst), David Kowalski (Former Chief Risk Officer) and David Master (Global Chief Marketing Officer), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co